Drug intelligence / Profile preview

GliSODin (Isocell Nutra)

Development stage
Preclinical
Lead developer
Isocell Nutra
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

GliSODin is an orally administered nutraceutical supplement that combines superoxide dismutase (SOD) derived from cantaloupe melon (Cucumis melo L.C.) with gliadin, a protein from wheat. The gliadin component functions as a biopolymer coating, protecting the SOD enzyme from degradation in the gastrointestinal tract and enabling its absorption. By bolstering the body's primary antioxidant defenses, GliSODin works to reduce oxidative stress. It does this by catalyzing the conversion of superoxide radicals into less harmful molecules. It has been clinically studied as an adjunct therapy for non-segmental vitiligo (with phototherapy) and melasma, and is also marketed for general skin health, anti-aging, and to mitigate exercise-induced muscle damage. The product was developed by the French company Isocell Laboratories and is marketed by various partners, including PLT Health Solutions.

Brand names
GliSODin
Other names
superoxide dismutase + gliadingastro-protected superoxide dismutasegliadin-combined plant superoxide dismutase extract
02

Targets

NeuraminidaseGPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on GliSODin (Isocell Nutra).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GliSODin (Isocell Nutra).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call